Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunological Markers Predictive of Response and Toxicity to Checkpoint in Metastatic Non-Small-cell Lung Cancers

NCT04918836 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT04918836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04918836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunological Markers Predictive of Response and Toxicity to Checkpoint in Metastatic Non-Small-cell Lung Cancers
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Unknown status
Start date
April 8, 2021
Completion date
October 8, 2022
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer